Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 15, 2023 Post category:CD19/Scientific Publications Continue ReadingPresentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 13, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Poster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 12, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Presentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 9, 2023 Post category:CD19/Scientific Publications Continue ReadingPresentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR Post author:andrewkaretas Post published:December 21, 2021 Post category:CD19/Scientific Publications Continue ReadingALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR
ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing Post author:andrewkaretas Post published:December 17, 2021 Post category:CD19/Scientific Publications Continue ReadingALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing
First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study Post author:andrewkaretas Post published:June 1, 2021 Post category:CD19/Scientific Publications Continue ReadingFirst-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study
American Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study Post author:andrewkaretas Post published:May 1, 2020 Post category:CD19/Scientific Publications Continue ReadingAmerican Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study
American Society of Hematology (ASH) Dec. 2018 — UCART19 PALL and CALM Studies Post author:andrewkaretas Post published:December 1, 2018 Post category:CD19/Scientific Publications Continue ReadingAmerican Society of Hematology (ASH) Dec. 2018 — UCART19 PALL and CALM Studies
